Credits Available: 4.75 hours of AMA PRA Category 1 Credit™, ANCC, and ACPE. MOC Points Available

Description: Endometrial cancer is among the few cancers increasing in incidence and mortality in the United States. In its early stages, endometrial carcinoma has a five-year relative survival rate of 96%, but it decreases to 18% for those with metastases. Surprisingly, mortality has been increasing faster than incidence. This is attributed to increasing rates of advanced cancers, higher-risk histologies, and older age of first diagnosis. Yet, there have also been increases in diagnoses in women aged less than 50 years, based on Surveillance, Epidemiology, and End Results (SEER) program data. While the incidence and mortality has been increasing across all racial groups, the rate of increase for Black women has been the steepest. Adjusting for the higher rate of hysterectomy in Black women compared with White women, the differing rates of this cancer in these groups exemplify this racial disparity. These statistics demonstrate the need for new therapeutics and subsequent education on their use in this field. To improve clinical outcomes, clinicians treating patients for advanced/recurrent endometrial cancer need to understand biomarker testing and molecular classification of disease, newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events. To these ends, this educational initiative will allow clinicians managing patients with advanced/recurrent endometrial cancer to learn and discuss the crucial points in diagnosing and managing these patients to best increase long-term survival.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Pharmacist, Nurse
Target Specialties: Gynecologic Oncology, Oncology

Dana Chase

David Geffen School of Medicine at UCLA
Associate Professor

I am a board-certified gynecologic oncologist in the Division of Gynecologic Oncology at the David Geffen School of Medicine. I also serve as a Co-Investigator for the NRG Oncology cooperative group and GOG-Partners Program. I have been an active member of the NRG Cancer Prevention and Control Committee, Health Outcomes Committee, and Cervix Committee. I also serve on the Investigator Council of GOG Partners. My research interests include QOL during cancer treatment and survivorship, symptom management, supportive and palliative care, and clinical trials in gynecologic cancers. I have authored over 100 peer-reviewed articles along with over 40 abstracts dealing predominantly with the prevention and chemotherapy of gynecologic malignancies as well as QOL, health disparities, and symptom management. I currently have an active clinical and research-oriented practice involving enrollment on clinical trials, cancer survivorship, quality of life, and disparities for gynecologic malignancy. I am the fellowship program director at my institution.